Back to Search
Start Over
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial
- Source :
- The Lancet Gastroenterology & Hepatology; November 2020, Vol. 5 Issue: 11 p996-1007, 12p
- Publication Year :
- 2020
-
Abstract
- The laxative drug lubiprostone improves intestinal permeability in healthy volunteers. We aimed to assess efficacy and safety of lubiprostone in patients with non-alcoholic fatty liver disease (NAFLD) with constipation via attenuation of intestinal permeability.
Details
- Language :
- English
- ISSN :
- 24681253
- Volume :
- 5
- Issue :
- 11
- Database :
- Supplemental Index
- Journal :
- The Lancet Gastroenterology & Hepatology
- Publication Type :
- Periodical
- Accession number :
- ejs53997349
- Full Text :
- https://doi.org/10.1016/S2468-1253(20)30216-8